stockportfolio.pro
CytomX Therapeutics, Inc. (CTMX)
Healthcare · Biotechnology · NasdaqGS
CytomX Therapeutics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.04M | $71.62M | $59.50M | $26.90M | $68.43M | $37.31M | $53.16M | $101.21M | $138.10M | $76.20M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-58.90M | $-43.10M | $-84.60M | $-132.82M | $-64.82M | $-115.87M | $-99.32M | $-569,000 | $31.87M | $-17.37M |
| Net margin | -391.5% | -60.2% | -142.2% | -493.7% | -94.7% | -310.5% | -186.8% | -0.6% | 23.1% | -22.8% |
Source: CytomX Therapeutics, Inc. SEC filings (10-K). 13 years of history available in the interactive view.
Explore 13 years of CytomX Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CTMX in your portfolio →
CytomX Therapeutics, Inc. financial history by metric
About CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
CytomX Therapeutics, Inc. — frequently asked questions
What is CytomX Therapeutics, Inc.'s revenue?
CytomX Therapeutics, Inc. (CTMX) reported revenue of $76.20M for fiscal year 2025, down 44.8% from the prior year, according to its SEC filings.
Is CytomX Therapeutics, Inc. profitable?
No — CTMX reported a net loss of $-17.37M in fiscal 2025.
What is CTMX's P/E ratio?
CytomX Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is CytomX Therapeutics, Inc. growing?
CTMX's revenue grew at roughly 2.2% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does CytomX Therapeutics, Inc. have?
As of fiscal year 2025, CTMX carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is CytomX Therapeutics, Inc.'s market cap?
CytomX Therapeutics, Inc. (CTMX) has a market capitalization of about $647.67M, based on the latest data in our nightly-refreshed cache.
When does CytomX Therapeutics, Inc.'s fiscal year end?
CTMX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from CytomX Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 13 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.